Last reviewed · How we verify

Jetrea — Competitive Intelligence Brief

Jetrea (OCRIPLASMIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteolytic Enzyme. Area: Ophthalmology.

marketed Proteolytic Enzyme Ophthalmology Recombinant protein Live · refreshed every 30 min

Target snapshot

Jetrea (OCRIPLASMIN) — Thrombogenics, Inc.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Jetrea TARGET OCRIPLASMIN Thrombogenics, Inc marketed Proteolytic Enzyme 2012-01-01
Wobenzym® plus Wobenzym® plus Mucos Pharma GmbH & Co. KG marketed Proteolytic enzyme combination
Trypsin-Chymotrypsin Trypsin-Chymotrypsin Dow University of Health Sciences marketed Proteolytic enzyme combination Protein substrates and fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proteolytic Enzyme class)

  1. Thrombogenics, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jetrea — Competitive Intelligence Brief. https://druglandscape.com/ci/ocriplasmin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: